Valuation: Vaxart, Inc.

Market Cap 131M 114M 106M 97.62M 184M 12.56B 187M 1.26B 494M 6.15B 491M 480M 21.18B P/E 2026 *
-2.78x
P/E 2027 * -0.54x
Enterprise Value 131M 114M 106M 97.62M 184M 12.56B 187M 1.26B 494M 6.15B 491M 480M 21.18B EV / Sales 2026 *
0.65x
EV / Sales 2027 * 55.7x
Free-Float
98.36%
Yield 2026 *
-
Yield 2027 * -
1 day+1.47%
1 week-0.05%
Current month-9.09%
1 month-4.35%
3 months-22.54%
6 months+0.18%
Current year+58.78%
1 week 0.52
Extreme 0.5201
0.59
1 month 0.49
Extreme 0.488
0.65
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
10.33
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/04/2021
Date Insider Type Main position Quantity % Market Cap.
05-22Buy

Director

10,000 0.0041%
05-19Tax

Chief Financial Officer

-31,395 0.0130%
04-23Free

Director

236,200 0.0982%
Change 5-day change 1-year change 3-year change Capi.($)
+1.47%-0.05%+27.91%-28.57% 131M
+6.05%+3.69%+65.28%+89.94% 53.54B
+0.21%-6.37%+58.42%+128.79% 54.18B
+0.89%-2.42%+8.07%+434.51% 23.66B
+0.37%-4.13%-18.56%-16.48% 22.78B
+2.36%+1.06%+43.34%-6.14% 19.54B
-2.29%+1.78%+34.98%-28.10% 17.82B
-4.00%-7.88%+175.60%+343.60% 16.01B
-1.15%-4.83%+46.53%+627.30% 15.37B
-0.48%-2.30%+22.36%+187.62% 14.09B
Average +0.37%-2.54%+46.39%+173.25% 23.71B
Weighted average by Cap. +1.21%-0.47%+49.53%+163.88%

Financials

2026 *2027 *
Net sales 200M 175M 162M 150M 282M 19.25B 287M 1.93B 758M 9.43B 753M 736M 32.46B 2.35M 2.05M 1.9M 1.75M 3.3M 226M 3.36M 22.64M 8.88M 111M 8.83M 8.63M 381M
Net income -24.4M -21.33M -19.72M -18.22M -34.3M -2.34B -34.92M -235M -92.25M -1.15B -91.67M -89.64M -3.95B -266M -233M -215M -199M -374M -25.57B -381M -2.56B -1.01B -12.52B -1B -978M -43.11B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
14/07/26 $0.5500 +1.47% 317,434
13/07/26 $0.5421 -0.72% 258,324
10/07/26 $0.5460 -0.24% 331,273
09/07/26 $0.5473 -0.54% 297,131
08/07/26 $0.5503 0.00% 554,319
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5420USD
Average target price
3.333USD
Spread / Average Target
+514.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock